Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties.

about

Safety of Delafloxacin: Focus on Adverse Events of Special Interest

P2860

Q57822396-EA5ABD47-C049-4571-9E32-C57306B2EA35

P2860

Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties.

Item

http://www.wikidata.org/entity/Q55252138

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Delafloxacin: Place in Therapy ...... and Pharmacologic Properties.

@en

Delafloxacin: Place in Therapy ...... and Pharmacologic Properties.

@nl

type

Item

label

Delafloxacin: Place in Therapy ...... and Pharmacologic Properties.

@en

Delafloxacin: Place in Therapy ...... and Pharmacologic Properties.

@nl

prefLabel

Delafloxacin: Place in Therapy ...... and Pharmacologic Properties.

@en

Delafloxacin: Place in Therapy ...... and Pharmacologic Properties.

@nl

P1476

Delafloxacin: Place in Therapy ...... and Pharmacologic Properties.

@en

P2093

Michael J Rybak

http://www.w3.org/2001/XMLSchema#string

Nicholas J Mercuro

http://www.w3.org/2001/XMLSchema#string

Sarah C J Jorgensen

http://www.w3.org/2001/XMLSchema#string

Susan L Davis

http://www.w3.org/2001/XMLSchema#string

P2860

Safety concerns with fluoroquinolones

Antimicrobial safety: focus on fluoroquinolones

International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases

Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex

Gatifloxacin, an advanced 8-methoxy fluoroquinolone.

Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

Mechanisms of action and resistance of older and newer fluoroquinolones.

Application of fluoroquinolone pharmacodynamics.

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.

Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.

P2888

s40121-018-0198-x

P304

197-217

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40121-018-0198-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1101884740

http://www.w3.org/2001/XMLSchema#string

P698

29605887

http://www.w3.org/2001/XMLSchema#string

P932

5986682

http://www.w3.org/2001/XMLSchema#string

Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties.

about

P2860

P2860

Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P932